Grethe Nørskov Rasmussen
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Dr. Grethe Nørskov Rasmussen is a Chief Development Officer at FluoGuide A/S.
Dr. Rasmussen was previously employed as a Senior Vice President-Product Development by Ascendis Pharma A/S, a Vice President-Protein Science by Maxygen, Inc., and a Principal by Novo Nordisk A/S.
She received her doctorate degree from Technical University of Denmark.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FLUOGUIDE A/S 2,1 % | 31.12.2024 | 343 185 ( 2,1 % ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 01.01.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 01.01.2019 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Technical University of Denmark
Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
FluoGuide A/S
FluoGuide A/S Pharmaceuticals: MajorHealth Technology Engages in the development of drugs used for the improvement of surgical outcomes by making cancer fluorescent | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen